List view / Grid view

Shire

 

ADHD market predicted to reach $13.9 billion by 2024

8 September 2016 | By Niamh Louise Marriott, Digital Content Producer

The market for attention deficit hyperactivity disorder (ADHD) across the seven major markets (7MM) of the US, France, Germany, Italy, Spain, the UK, and Japan, is set to experience an increase from approximately $6.1 billion in 2014 to $13.9 billion by 2024, at a compound annual growth rate of 8.5%,…

FDA grants fast track for Shire’s NASH investigational treatment

29 July 2016 | By Mandy Parrett, Editorial Assistant

Shire Plc has announced today that the United States Food and Drug Administration (FDA) has granted Fast Track designation for SHP626 (volixibat) for an investigational treatment of adults with nonalcoholic steatohepatitis (NASH) with liver fibrosis.

Send this to a friend